What is GLP-2 and What Are Its Functions?

Glucagon-like peptide-2, or GLP-2, is a 33-amino-acid hormone produced in the gut that acts as the body’s primary signal for growing and maintaining the intestinal lining. Its discovery traces to an unexpected observation: tumors in mice that produced a precursor protein called proglucagon caused striking intestinal growth, which eventually led researchers to isolate GLP-2 as the molecule responsible.¹ Since that finding, GLP-2 has turned out to do far more than grow new gut tissue. It strengthens the intestinal barrier, boosts blood flow to the gut, influences fat absorption, suppresses inflammation, and even reaches the brain to affect appetite.

Where GLP-2 Comes From

GLP-2 is made by specialized cells in the intestinal lining called L-cells. These cone-shaped cells are scattered mainly through the lower small intestine and colon, and they respond to nutrients passing through the gut after a meal. L-cells produce a large precursor protein, proglucagon, which gets chopped into several smaller hormones depending on which enzyme does the cutting. In L-cells, an enzyme called prohormone convertase 1/3 does the work, and the result is a set of peptides that includes GLP-1, GLP-2, glicentin, and oxyntomodulin.² The same precursor processed in the pancreas by a different enzyme yields glucagon instead.³ Because GLP-1 and GLP-2 are carved from the same precursor by the same enzyme, they are always released together and in equal amounts after eating.

Why GLP-2 Disappears Quickly

Once released into the bloodstream, GLP-2 has a very short working life. An enzyme called dipeptidyl peptidase IV (DPP-IV), which is found on the surface of blood vessels and other tissues, snips the first two amino acids off the GLP-2 chain. That small cut is enough to inactivate the hormone.⁴ The result, a fragment called GLP-2(3-33), no longer stimulates the GLP-2 receptor. In animal experiments, serum from rats that genetically lacked DPP-IV could not break down GLP-2, confirming that this single enzyme is the main route of clearance.⁵ This rapid degradation is why natural GLP-2 has a half-life of only about seven minutes in humans, and why drug developers had to engineer a modified version (more on that later) to make it clinically useful.

The GLP-2 Receptor and How the Signal Spreads

The receptor for GLP-2 (GLP-2R) sits almost exclusively in the gastrointestinal tract, which is a sharp contrast to its sibling GLP-1, whose receptor is found in the pancreas, brain, heart, and elsewhere.⁶ Within the gut, the receptor has been localized to enteric neurons and certain endocrine cells rather than to the intestinal lining cells (enterocytes) themselves.⁷ That creates a puzzle: if GLP-2 promotes growth in epithelial cells but its receptor is not on those cells, how does the signal get there?

Research in mice has identified insulin-like growth factor 1 (IGF-1) as a key go-between. When GLP-2 activates its receptor on cells in the tissue underneath the lining, those cells ramp up production and secretion of IGF-1, which then acts on the epithelial cells to drive growth.⁸ The IGF-1 receptor on the surface of epithelial cells is required for GLP-2 to promote gut barrier integrity, linking these two functions through the same signaling chain.⁹ But IGF-1 is not the whole story. In mice engineered to lack two proteins that normally regulate IGF-1 activity, GLP-2 still managed to stimulate intestinal growth, apparently by switching to alternative growth-factor pathways including one involving the ErbB family of receptors.¹⁰ The takeaway is that GLP-2 uses multiple downstream mediators, giving the gut some redundancy in how it responds to this growth signal.

Growing and Maintaining the Intestinal Lining

The most studied function of GLP-2 is its ability to increase the mass and health of the intestinal lining. In early mouse experiments, GLP-2 treatment boosted the rate of crypt-cell proliferation (the dividing cells at the base of intestinal folds) from about 46% to 57%, while simultaneously cutting the rate of cell death in those same crypts from roughly 6% to under 3%.¹¹ That dual action, more new cells and fewer dying ones, led to measurable increases in small bowel weight across mice of all ages. Neonatal piglets fed intravenously (a model that causes the gut to shrivel from disuse) also showed dose-dependent improvements in mucosal growth when treated with GLP-2.¹²

Strengthening the Gut Barrier

Beyond just growing more lining, GLP-2 tightens the connections between intestinal cells. The gut barrier depends on proteins called tight junctions that seal the gaps between neighboring cells, preventing bacteria and toxins from leaking into the bloodstream. In cell-culture experiments modeling the intestinal wall, GLP-2 treatment increased the expression of two critical tight-junction proteins, occludin and ZO-1, by roughly 1.6-fold and nearly 5-fold respectively, and raised the overall electrical resistance of the cell layer, a standard measure of barrier integrity.¹³ The same pair of tight-junction proteins was upregulated in aged rats given GLP-2, and their intestinal permeability dropped accordingly.¹⁴ This barrier-sealing property is one reason GLP-2 interests researchers working on conditions involving “leaky gut.”

Boosting Blood Flow and Nutrient Uptake

After a meal, the gut needs more blood to absorb and carry away nutrients. GLP-2 plays a direct role in making that happen. In piglets fed intravenously (and thus nutrient-deprived in the gut), a single dose of GLP-2 increased portal blood flow by about 25% and intestinal blood volume by about 51%. At the same time, glucose uptake by the intestine rose roughly 90%.¹⁵ The blood-flow increase appears to involve nitric oxide, a well-known vasodilator: GLP-2 raised the activity of the enzyme that produces nitric oxide in the gut wall.¹⁶ In rats, both GLP-2 and another gut hormone (GIP) acutely increased blood flow through the superior mesenteric artery, the main vessel feeding the intestines.¹⁷

Effects on Fat Absorption

GLP-2’s influence on nutrient handling goes beyond glucose. It also ramps up fat absorption, an effect that is biologically useful when the gut needs to maximize calorie extraction but has some metabolic implications worth knowing about. In hamsters given olive oil, GLP-2 tripled the amount of triglyceride-rich lipoproteins (the particles that carry dietary fat from the gut into the bloodstream) and tripled cholesterol mass as well. The mechanism involved increased expression of CD36, a transporter protein that helps intestinal cells take up fatty acids.¹⁸

In humans, the picture is equally striking. When volunteers received a GLP-2 injection seven hours after a meal, with no additional food, levels of triglycerides and fat-carrying particles in the blood still surged, suggesting GLP-2 triggers release of fat that was already stored in the gut lining rather than requiring new food intake.¹⁹ This sets up an interesting dynamic with GLP-1: the two hormones are secreted together in equal amounts, yet GLP-1 suppresses chylomicron production while GLP-2 stimulates it. Under normal conditions, GLP-2’s pro-lipid effect appears to dominate, meaning that the net result after a fatty meal leans toward higher fat absorption rather than lower.²⁰

Anti-Inflammatory Actions

GLP-2 does more than build tissue. It also actively dampens inflammation in the gut. In mouse models of both small-intestinal and colonic inflammation, GLP-2 treatment significantly reduced levels of pro-inflammatory molecules (including TNF-alpha and IFN-gamma), lowered tissue damage scores, and raised the anti-inflammatory cytokine IL-10. These effects held whether the treatment was given at the onset of inflammation or delayed until the inflammation was already established. The anti-inflammatory action appeared to work through activation of VIP-producing neurons in the gut wall, independently of GLP-2’s growth-promoting effects.²¹ A separate study using a degradation-resistant GLP-2 analog found that it reversed weight loss, reduced inflammatory markers, and increased colon mucosal area in mice with acute colitis.²² These results have fueled interest in GLP-2 as a potential adjunct treatment for inflammatory bowel disease, though clinical trials in humans for that specific purpose are still limited.

GLP-2 and Bone

A more recently appreciated function of GLP-2 is its effect on bone turnover. After eating, bone breakdown temporarily slows, and researchers have identified GLP-2 as one of the gut hormones responsible. In a study of people with type 2 diabetes, a subcutaneous injection of GLP-2 suppressed a key marker of bone resorption (CTX) to about 74% of baseline levels within three hours, a statistically significant reduction compared with placebo.²³ This finding connects gut nutrition to skeletal health in a direct hormonal pathway and raises the possibility that GLP-2-based therapies could eventually help protect against osteoporosis, although that application remains speculative for now.

Reaching the Brain

Despite its receptor being concentrated in the gut, GLP-2 also acts on the brain. When a degradation-resistant GLP-2 analog was injected directly into the brain ventricles of mice, it suppressed food and water intake within two hours and caused acute weight loss. The injection activated neurons across several hypothalamic regions involved in appetite regulation, including areas that produce both appetite-stimulating and appetite-suppressing neuropeptides.²⁴ GLP-2 also appears to influence appetite from outside the brain by slowing gastric emptying through vagal nerve pathways, creating a dual central-peripheral system that modulates how hungry you feel after eating. Whether these brain effects have meaningful relevance in everyday human physiology, given GLP-2’s very short half-life, remains an open question.

Clinical Use in Short Bowel Syndrome

The clearest translation of GLP-2 science into medicine is teduglutide, a synthetic GLP-2 analog approved for treating short bowel syndrome (SBS). Teduglutide differs from natural GLP-2 by a single amino acid substitution that makes it resistant to DPP-IV cleavage, extending its half-life from minutes to hours and allowing once-daily injection. SBS patients have lost so much intestine, through surgical removal or disease, that they cannot absorb enough nutrition from food and depend on intravenous feeding (parenteral support). The goal of teduglutide is to enhance what intestine remains, coaxing it to absorb more so that patients can reduce or eliminate their IV nutrition.

In a pivotal 24-week trial, teduglutide reduced weekly parenteral support volume by an average of about 4 to 8 liters depending on the treatment group, corresponding to reductions of roughly 28% to 66%.²⁵ Long-term follow-up in the STEPS-3 extension study showed that the benefits held and even deepened: patients who had been on teduglutide from the start saw an average reduction of about 50% in their weekly parenteral support, and some patients achieved complete independence from IV nutrition.²⁶ For children with SBS, who face the additional challenge of growing while nutritionally deprived, GLP-2 analogs have similarly shown benefits in reducing parenteral nutrition dependence and improving enteral autonomy.²⁷

How GLP-2 Compares to GLP-1

Because GLP-1 and GLP-2 come from the same precursor and are always released together, they are natural points of comparison. GLP-1 has become globally famous through drugs like semaglutide and liraglutide, which mimic its effects for diabetes and weight loss. The two peptides are close siblings, yet their functions barely overlap. GLP-1 acts mainly through its receptor in the pancreas (stimulating insulin secretion), the brain (suppressing appetite), and the stomach (slowing emptying). GLP-2’s receptor sits almost entirely in the gut, and its primary role is structural: building and maintaining the intestinal lining.⁶ Even on fat metabolism, as described earlier, they pull in opposite directions. Both are degraded by DPP-IV with similarly short half-lives, but the drug strategies that emerged from each are wildly different: GLP-1 drugs target metabolic disease and obesity, while GLP-2 drugs target intestinal failure. The fact that the body releases them simultaneously suggests evolution found value in coupling a metabolic regulator with a gut maintenance signal every time nutrients arrive.

Safety Concerns Around Gut Growth

A hormone that promotes cell proliferation in the gut inevitably raises questions about cancer risk. In animal studies, exogenous GLP-2 increased the growth and incidence of colon adenomas in rodents that already had pre-existing tumors or were given a chemical carcinogen.²⁸ A systematic review of the evidence concluded that GLP-2 treatment in animals with pre-induced cancer may promote growth of existing tumors, though it did not initiate cancer on its own in healthy tissue.²⁹ In practice, this means patients on teduglutide undergo regular colonoscopic surveillance. The clinical trial data in SBS patients has not revealed a clear increase in cancer rates, but the treated population is small and the follow-up periods are relatively short compared with the decades over which colorectal cancers develop. Clinicians generally consider the risk manageable given the serious health burden of intestinal failure, but it remains a reason why teduglutide is not prescribed casually.

An Ancient Hormone

GLP-2 is not a recent evolutionary invention. Phylogenetic analyses of receptor genes show that the GLP-2 receptor, along with receptors for glucagon, GLP-1, and GIP, originated very early in vertebrate evolution. All of these receptors were already present in the common ancestor of land animals and bony fish, meaning this system for managing gut maintenance through hormonal signaling has been conserved for hundreds of millions of years.²⁰ That deep conservation underscores how fundamental the gut-trophic role of GLP-2 is: vertebrates across vastly different diets and body plans have maintained this hormone and its receptor essentially unchanged, suggesting that nutrient-triggered intestinal growth is not optional but a core survival mechanism.